Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma

Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma

Programmed cell death ligand 1 (PD-L1) inhibitors are commonly used in treating advanced-stage urothelial carcinoma (UC). Therefore, this study evaluated the relationship between PD-L1 expression in circulating tumor cells (CTCs) and treatment response to PD-L1 inhibitors using blood samples collect...

Full description

Bibliographic Details
Main Authors: Pei-Jhang Chiang, Ting Xu, Tai-Lung Cha, Yi-Ta Tsai, Shu-Yu Liu, Sheng-Tang Wu, En Meng, Chih-Wei Tsao, Chien-Chang Kao, Chin-Li Chen, Guang-Huan Sun, Dah-Shyong Yu, Sun-Yran Chang, Ming-Hsin Yang
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Biology
Subjects:
urothelial carcinoma
circulating tumor cells
PD-L1
PD-L1 inhibitors
Online Access:https://www.mdpi.com/2079-7737/10/7/674

Similar Items

Similar Items